Polgenix, Inc. is a biotech company established in 2006, focusing on two primary areas: drug discovery and innovative imaging technologies. The company specializes in targeting G protein-coupled receptors (GPCRs), which are critical in the development of treatments for common blinding diseases. This approach aims to leverage the biological pathways associated with GPCRs to create effective therapeutic options for patients suffering from vision impairments. Additionally, Polgenix is dedicated to advancing high-resolution retinal imaging techniques, which play a vital role in ophthalmic drug discovery by providing detailed insights into retinal health and disease progression.

The team at Polgenix comprises experienced professionals, including Richard Sutkus, Ph.D., as CEO, and Krzysztof Palczewski, Ph.D., as Chief Scientific Officer, alongside a skilled group of scientists and administrators. Their collective expertise supports the company's mission to innovate in both drug development and imaging technologies, ultimately enhancing the understanding and treatment of ocular diseases. By integrating cutting-edge research with practical applications, Polgenix aims to contribute significantly to the field of ophthalmology and improve patient outcomes.

Polgenix

Company Details